tolbutamide has been researched along with clofibrate in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (48.15) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 11 (40.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Ryan, JR | 1 |
| Jain, AK; McMahon, FG; Ryan, JR | 1 |
| Friedberg, SJ; Kudzma, DJ | 1 |
| Kapoor, A; Veronich, K; White, G | 1 |
| Ceruso, D; Frisina, N; Nicita-Mauro, V | 1 |
| Bertazzoni, A; Ferrari, C; Frezzati, S; Testori, GP | 1 |
| Baba, S; Yokono, K; Zeng, SF | 1 |
| Sellers, E; Weser, JK | 1 |
| Eipe, J | 1 |
| Miller, M; Moses, AM | 1 |
| Clarke, BF; Duncan, LJ | 1 |
| Abrams, WB; Reich, S; Solomon, HM; Spirt, N | 1 |
| Scherff, R; Schulze-Schleppinghoff, B; Vogelberg, KH | 1 |
5 review(s) available for tolbutamide and clofibrate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions with coumarin anticoagulants. 2.
Topics: Allopurinol; Anabolic Agents; Animals; Anti-Bacterial Agents; Anticoagulants; Barbiturates; Chloral Hydrate; Chloramphenicol; Cholestyramine Resin; Clofibrate; Contraceptives, Oral; Coumarins; Dextrothyroxine; Diuretics; Drug Antagonism; Drug Synergism; Ethacrynic Acid; Ethanol; Glucagon; Glucocorticoids; Glutethimide; Humans; Oxyphenbutazone; Phenylbutazone; Quinidine; Quinine; Quinolines; Salicylates; Sulfinpyrazone; Sulfonamides; Thyroid Hormones; Tolbutamide | 1971 |
Drugs affecting therapy with anticoagulants.
Topics: Anticoagulants; Chloramphenicol; Clofibrate; Contraceptives, Oral; Coumarins; Diuretics; Drug Interactions; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Estrogens; Ethanol; Heparin; Humans; Hypnotics and Sedatives; Phenylbutazone; Phenytoin; Salicylates; Thyroxine; Tolbutamide; Vitamin K | 1972 |
Drug-induced dilutional hyponatremia.
Topics: Acetaminophen; Amitriptyline; Animals; Anura; Body Fluids; Carbamazepine; Chlorpropamide; Clofibrate; Cyclophosphamide; Diabetes Insipidus; Diabetes Mellitus; Diazoxide; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Hyponatremia; Kidney; Rats; Sodium; Sulfonylurea Compounds; Tolbutamide; Urinary Bladder; Vasopressins; Vincristine; Water Intoxication; Water-Electrolyte Balance | 1974 |
Advances in the treatment of diabetes mellitus.
Topics: Blood Glucose; Chlorpropamide; Clofibrate; Diabetes Mellitus; Diabetic Coma; Diabetic Ketoacidosis; Diabetic Retinopathy; Diet Therapy; Humans; Hypoglycemia; Insulin; Kidney Transplantation; Lactates; Light Coagulation; Metformin; Methods; Pancreas Transplantation; Phenformin; Pituitary Gland; Renal Dialysis; Sulfonylurea Compounds; Tolbutamide | 1971 |
4 trial(s) available for tolbutamide and clofibrate
| Article | Year |
|---|---|
The metabolic spectrum of halofenate.
Topics: Blood Glucose; Cholesterol; Clinical Trials as Topic; Clofibrate; Creatine Kinase; Glycolates; Halofenate; Humans; Hyperlipidemias; Probenecid; Protein Binding; Thyroid Function Tests; Thyroxine; Tolbutamide; Triglycerides; Uric Acid | 1975 |
Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
Topics: Adult; Clinical Trials as Topic; Clofibrate; Diabetes Complications; Diabetes Mellitus; Drug Synergism; Female; Glycolates; Halofenate; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipoproteins, VLDL; Male; Middle Aged; Phenformin; Sulfonylurea Compounds; Tolbutamide; Triglycerides | 1975 |
Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
Topics: Blood Glucose; Chlorpropamide; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Drug Synergism; Glycolates; Halofenate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Phenformin; Tolazamide; Tolbutamide | 1977 |
[The influence of clofibrate on glucose metabolism in diabetes mellitus without endogenous hypertriglyceridemia (author's transl)].
Topics: Adult; Aged; Blood Glucose; Clofibrate; Diabetes Mellitus; Female; Humans; Insulin; Male; Middle Aged; Tolbutamide; Triglycerides | 1982 |
18 other study(ies) available for tolbutamide and clofibrate
| Article | Year |
|---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effects of phenylbutazone, tolbutamide, and clofibric acid on binding of racemic warfarin and its enantiomers to human serum albumin.
Topics: Binding, Competitive; Clofibrate; Clofibric Acid; Humans; Kinetics; Phenylbutazone; Protein Binding; Serum Albumin; Stereoisomerism; Tolbutamide; Warfarin | 1979 |
[Clofibrate and carbohydrate metabolism: behavior of blood insulin in patients with blood lipid disorders].
Topics: Adult; Age Factors; Aged; Arteriosclerosis; Blood Glucose; Carbohydrate Metabolism; Clofibrate; Female; Glucose Tolerance Test; Humans; Hyperlipidemias; Insulin; Male; Middle Aged; Tolbutamide | 1975 |
Potentiation of hypoglycemic response to intravenous tolbutamide by clofibrate.
Topics: Clofibrate; Diabetes Mellitus; Drug Synergism; Humans; Tolbutamide | 1976 |
Effects of sulfonylureas and clofibrate on insulin receptors in cultured human lymphocytes.
Topics: Cells, Cultured; Clofibrate; Gliclazide; Humans; Insulin; Lymphocytes; Receptor, Insulin; Sulfonylurea Compounds; Tolbutamide | 1985 |
Interactions between digitoxin and other drugs in vitro and in vivo.
Topics: Binding Sites; Cell Membrane Permeability; Chemical Phenomena; Chemistry; Clofibrate; Digitoxin; Digoxin; Drug Antagonism; Enzyme Induction; Erythrocytes; Humans; Microsomes, Liver; Phenobarbital; Phenylbutazone; Phenytoin; Protein Binding; Radioisotopes; Rubidium; Serum Albumin; Sulfadimethoxine; Tolbutamide; Tritium; Warfarin | 1971 |